Dr. Kamel Ben-Othmane, MD

Dr. Ben-Othmane practices at Riverside Regional Medical Center in Newport News, Virginia, part of Riverside Health System.

Dr. Ben-Othmane's NPI, 1316966328, was assigned on July 19, 2006. Dr. Ben-Othmane holds Virginia license 0101231651.

Dr. Ben-Othmane's primary practice is Riverside Regional Medical Center, at 500 J Clyde Morris Blvd, Newport News, VA 23601 in Newport News City. The practice phone is (757) 594-2000.

Dr. Ben-Othmane's primary practice is Riverside Regional Medical Center in Newport News, Virginia, part of Riverside Health System. Dr. Ben-Othmane is also affiliated with Bon Secours Mary Immaculate Hospital. The medical group on file is Riverside Gastroenterology Specialists. Dmand AI also links Dr. Ben-Othmane to 3 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Ben-Othmane practices, 6 sites in all. Vendor and product names are available with a free account.

Neurology is Dr. Ben-Othmane's primary specialty in the NPI Registry, under taxonomy code 2084N0400X. Dr. Ben-Othmane is licensed in Virginia.

CMS data shows 1,490 Medicare services from Dr. Ben-Othmane across 16 procedure codes in 2024, for 707 Medicare patients. Medicare paid $78,033 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 707 Medicare patients who saw Dr. Ben-Othmane in 2024. The largest group is 75 to 84, with 281 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 7% are also on Medicaid. Their average risk score is 1.39, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Ben-Othmane's median patient age at 56, with 72% women.

In 2024, Dr. Ben-Othmane wrote 4,521 Medicare Part D claims for 494 patients. 86% of them were for generic drugs. CMS names the drug for 4,213 of them, across 71 drugs with 11 or more claims each, at $736,288 in total drug cost. In 2023, CMS named 3,385 claims across 61 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 95 out of 100 for Dr. Ben-Othmane for performance year 2024, reported through an alternative payment model (APM). Dr. Ben-Othmane accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Ben-Othmane as offering telehealth.

CMS Open Payments shows 118 general payments to Dr. Ben-Othmane from 23 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 96% of the total. Biogen, Inc. paid the most, $1,121.